Actinium Pharmaceuticals’ (ATNM) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research report released on Tuesday morning, Benzinga reports. They currently have a $21.00 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Actinium Pharmaceuticals’ FY2024 earnings at ($1.35) EPS.

Other analysts have also issued reports about the company. Maxim Group increased their target price on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a buy rating in a report on Tuesday, March 19th. StockNews.com raised shares of Actinium Pharmaceuticals from a sell rating to a hold rating in a report on Monday, April 29th. Finally, HC Wainwright reaffirmed a buy rating and set a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, April 29th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $25.72.

Actinium Pharmaceuticals Trading Up 1.8 %

Actinium Pharmaceuticals stock opened at $8.91 on Tuesday. The stock has a market capitalization of $265.34 million, a price-to-earnings ratio of -5.21 and a beta of 0.08. Actinium Pharmaceuticals has a twelve month low of $4.00 and a twelve month high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.21. The firm had revenue of $0.08 million for the quarter. As a group, equities analysts forecast that Actinium Pharmaceuticals will post -1.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Brandywine Global Investment Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth approximately $1,033,000. Sanders Morris Harris LLC bought a new stake in Actinium Pharmaceuticals during the 1st quarter valued at $78,000. Finally, Creative Financial Designs Inc. ADV raised its holdings in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after buying an additional 3,175 shares during the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.